Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024

Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements; - production of mineral waters, beverages and foods (2.1%); - other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc. Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%). Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),